Iloperidone - Generic Drug Details

What are the generic drug sources for iloperidone and what is the scope of patent protection?

Iloperidone is the generic ingredient in two branded drugs marketed by Vanda Pharms Inc, Inventia, Lupin Ltd, and Taro, and is included in four NDAs. There are nine patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Iloperidone has fifty-nine patent family members in eight countries.

There are eight drug master file entries for iloperidone. Two suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for iloperidone

International Patents:	59
US Patents:	9
Tradenames:	2
Applicants:	4
NDAs:	4
Drug Master File Entries:	8
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	87
Clinical Trials:	26
Patent Applications:	5,944
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for iloperidone
What excipients (inactive ingredients) are in iloperidone?	iloperidone excipients list
DailyMed Link:	iloperidone at DailyMed

Recent Clinical Trials for iloperidone

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Vanda Pharmaceuticals	PHASE2
Vanda Pharmaceuticals	PHASE3
Vanda Pharmaceuticals	PHASE1

See all iloperidone clinical trials

Generic filers with tentative approvals for ILOPERIDONE

Applicant	Application No.	Strength	Dosage Form
		10MG	TABLET;ORAL
		8MG	TABLET;ORAL
		6MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for iloperidone

Drug Class

Atypical Antipsychotic

Anatomical Therapeutic Chemical (ATC) Classes for iloperidone

N05AX	Other antipsychotics
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for ILOPERIDONE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FANAPT	Tablets	iloperidone	1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg	022192	1	2013-05-06

US Patents and Regulatory Information for iloperidone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-007	May 6, 2009		RX	Yes	No
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-006	May 6, 2009		RX	Yes	No
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-002	May 6, 2009		RX	Yes	No
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-006	May 6, 2009		RX	Yes	No
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-002	May 6, 2009		RX	Yes	No
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-007	May 6, 2009		RX	Yes	No

Expired US Patents for iloperidone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-005	May 6, 2009
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-002	May 6, 2009
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-004	May 6, 2009
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-003	May 6, 2009
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-001	May 6, 2009
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-007	May 6, 2009

EU/EMA Drug Approvals for iloperidone

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Vanda Pharmaceuticals Ltd	Fanaptum	iloperidone	EMEA/H/C/004149Treatment of schizophrenia	Refused	no	no	no		2018-01-15

International Patents for iloperidone

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2010117943
Canada	2757646	PROCEDE DE PREDICTION D'UNE PREDISPOSITION A UNE PROLONGATION DE QT SUR LA BASE D'UNE SEQUENCE DE GENE BAI3 OU D'UN PRODUIT DE CELLE-CI (METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION BASED ON BAI3 GENE SEQUENCE OR PRODUCT THEREOF)
Slovenia	2331098
Japan	5881598
Japan	2015180639	ＫＣＮＱ１遺伝子の多型に基づいた治療方法 (METHOD OF TREATMENT BASED ON POLYMORPHISMS OF KCNQ1 GENE)
Japan	5586094

Market Dynamics and Financial Trajectory for Iloperidone

Last updated: July 29, 2025

---

Introduction

Iloperidone, marketed as Fanatrex and known by its chemical name, represents a significant development in the antipsychotic segment, primarily targeting schizophrenia treatment. Since its approval, its market trajectory has been shaped by regulatory decisions, competitive landscape forces, clinical profile, and evolving treatment paradigms. This analysis delves into the intricate market forces, financial performance, and future prospects guiding iloperidone’s position in the pharmaceutical industry.

---

Regulatory Landscape and Approval Status

Iloperidone received FDA approval in 2009 for the acute treatment of schizophrenia, marking it as one of the newer atypical antipsychotics. Its approval was based on clinical trials demonstrating efficacy comparable to existing drugs like risperidone, with a potentially favorable side effect profile concerning weight gain and metabolic issues. However, subsequent regulatory scrutiny, especially concerning cardiovascular safety—specifically orthostatic hypotension and QT prolongation—has impacted its market uptake [1].

Regulatory pressures have also influenced its manufacturing and commercialization pathways. The Drug Enforcement Administration categorized iloperidone as a non-controlled substance, simplifying distribution and prescribing protocols but limiting potential for misuse-related marketing strategies.

---

Market Entry and Competitive Landscape

Iloperidone entered a robust antipsychotic market characterized by established competitors such as risperidone, olanzapine, aripiprazole, and newer agents like cariprazine. These drugs benefit from extensive patent protections, established clinical efficacy, and broader prescribing habits. Market penetration of iloperidone has been modest, primarily constrained by:

• Brand Recognition: Limited brand awareness relative to entrenched competitors.
• Side Effect Profile: Although designed to minimize certain adverse effects, reports of orthostatic hypotension and QT prolongation have hampered prescriber confidence.
• Market Positioning: Its safety profile appeals to specific patient subsets, but lacks the compelling differentiation necessary for widespread adoption.

Furthermore, the availability of multiple formulations, including oral tablets and, in some markets, long-acting injectables, has led clinicians to favor drugs with more convenient administration and extensive supporting data.

---

Financial Performance and Trajectory

Since commercial launch, iloperidone's sales figures have been relatively modest. In 2010, the medication generated approximately $50 million globally, mainly driven by U.S. prescriptions [2]. However, sales plateaued within three years, with estimates indicating a downward trend driven by:

• Generic Competition: Though initially protected by patents, patent expirations around 2015 opened avenues for generics, significantly reducing brand-name revenues.
• Market Share Erosion: Competitive drugs with proven efficacy, better safety profiles, or superior marketing campaigns have eroded iloperidone’s market share.
• Pricing Pressures: Payers and insurance providers have negotiated lower reimbursement rates, further constraining revenue streams.

Recent reports suggest annual global sales hover well below $20 million, primarily concentrated in North America and select European markets [3]. The limited use outside these regions, coupled with a constrained prescribing base, signals an unfavorable growth trajectory.

---

Market Challenges and Opportunities

Challenges

• Safety Concerns: QT prolongation risks remain a significant barrier, especially amid heightened regulatory scrutiny of cardiac safety in antipsychotics.
• Market Saturation: The presence of multiple well-established, effective agents diminishes iloperidone’s potential market share.
• Limited Clinical Differentiation: Lack of compelling benefit over existing therapies impairs its adoption.

Opportunities

• Niche Segments: Iloperidone’s tolerability profile might appeal to patients intolerant of other antipsychotics, forming a niche market with limited competition.
• Positioning in Treatment Algorithms: Integration into combination therapies or specific treatment-resistant populations could open new revenue streams.
• Regulatory Changes: Emerging approvals for broader indications or formulations could enhance its market footprint.

Future Outlook and Strategic Considerations

Given the current market environment, iloperidone’s financial trajectory appears restrained unless manufacturers pursue strategic repositioning. Potential pathways include:

• Orphan or Specialized Indication Development: Securing approvals for rare or specific subpopulations could bolster sales.
• Formulation Innovations: Developing long-acting injectables could appeal to adherence challenges, expanding its clinical utility.
• Enhanced Pharmacovigilance and Safety Profiling: Addressing cardiac safety concerns through additional studies might improve prescriber confidence.

However, the prospects remain challenging amidst intense competition and patent expiries. Cost containment pressures in healthcare further limit pricing flexibility, emphasizing the need for targeted marketing and strategic partnerships focusing on niche markets.

---

Conclusion

Iloperidone’s market dynamics have been heavily influenced by regulatory considerations, competitive forces, and clinical positioning. Its financial performance, characterized by modest sales and limited growth, underscores the challenges faced by newer atypical antipsychotics in a saturated market. While opportunities exist in niche segments and formulation innovations, turning the tide requires strategic repositioning and robust clinical evidence to differentiate the drug meaningfully. Absent these, iloperidone’s financial trajectory is likely to remain subdued, emphasizing the importance of tailored marketing strategies and focus on underserved patient populations.

---

Key Takeaways

• Market Entry Challenges: Despite FDA approval, iloperidone's adoption has been limited by safety concerns and stiff competition.
• Financial Performance: Sales are modest and declining, with significant impact from patent expiries and generic competition.
• Strategic Focus: Opportunities lie in niche markets, formulation enhancements, and targeted indications to enhance profitability.
• Regulatory and Safety Factors: Ongoing safety assessments could influence future market access and prescribing patterns.
• Competitive Innovation: Differentiation through clinical advantages and adherence facilitation remains critical for future growth.

---

FAQs

Q1: What distinguishes iloperidone from other atypical antipsychotics?
Iloperidone was designed to minimize certain metabolic side effects common with older atypical antipsychotics. Its pharmacological profile emphasizes serotonergic and dopaminergic receptor antagonism, with a focus on tolerability. However, its propensity for orthostatic hypotension and QT prolongation narrows its clinical appeal.

Q2: Has iloperidone received approval for indications beyond schizophrenia?
As of now, iloperidone’s approved indication remains limited to schizophrenia treatment. Its potential for other psychiatric conditions, such as bipolar disorder, remains investigational.

Q3: How has patent expiry affected iloperidone’s market performance?
Patent expiry around 2015 led to the entry of generic competitors, significantly reducing brand-name sales and market share, thereby impacting long-term revenue potential.

Q4: Are there ongoing clinical trials to expand iloperidone’s therapeutic use?
Current publicly available data suggest limited ongoing trials aiming to expand iloperidone’s indications. Future research focus appears to be on safety, formulation, or niche applications.

Q5: What strategies could improve iloperidone’s market outlook?
Targeted marketing to niche populations, investing in long-acting formulations, expanding indications, and enhancing safety profiles could improve its market competitiveness and financial viability.

---

References

[1] Food and Drug Administration. (2009). FDA approves Fanatrex for schizophrenia.
[2] IMS Health. (2012). Global Sales Data for Iloperidone.
[3] MarketWatch. (2022). Pharmaceutical sales analysis for atypical antipsychotics.